Skip to main content

Table 2 Adverse events (n = 17)

From: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Adverse Event Grade 1 Grade 2 Grade 3 Grade 4
Hematology
 Anemia 3 2 4 0
 Leukopenia 4 1 1 0
 Lymphopenia 0 2 1 1
 Neutropenia 0 0 1 0
 Thrombocytopenia 3 0 1 0
Gastrointestinal Disorders
 Abdominal pain 1 0 0 0
 Anorexia 1 1 0 0
 AST increased 1 0 0 0
 Bloating 0 1 0 0
 Dysgeusia 0 1 0 0
 Dyspepsia 2 0 0 0
 Diarrhea 6 3 0 0
 Nausea 8 1 2 0
 Oral mucositis 0 1 1 0
 Vomiting 6 0 1 0
Cardiovascular
 Hypertension 0 0 1 0
Infection
 Lung 0 0 1 0
 Tenosynovitis 0 0 1 0
 Urinary tract 0 1 0 0
Endocrine and Chemistry
 Hypothyroidism 0 1 0 0
Nervous System
 Dizziness 1 0 0 0
 Headache 1 0 0 0
 Paresthesia 1 0 0 0
 Syncope 0 0 1 0
Respiratory, Thoracic, and Mediastinal
 Dyspnea 1 0 0 0
 Cough 1 1 0 0
Eye Disorders
 Blurred vision 1 0 0 0
 Optic nerve disorder 0 1 0 0
Ear and Labyrinth Disorders
 Hearing impairment 0 1 1 0
 Tinnitus 1 0 0 0
General
 Fatigue 1 2 1 0
 Edema, limbs 1 0 0 0
 Localized edema 1 0 0 0
 Pain, extremity 0 1 0 0
 Weight loss 1 0 0 0
Musculoskeletal and Connective Tissue
 Arthralgia 2 0 0 0
 Arthritis 0 1 0 0
 Myalgia 2 0 0 0
 Musculoskeletal/connective tissue, leg cramps 1 1 0 0
 Musculoskeletal/connective tissue, muscle cramps 0 0 1 0
 Muscle weakness, lower limb 0 0 1 0
Skin, Subcutaneous Tissue
 Erythema 1 0 0 0
 Pruritis 1 0 0 0
 Rash, maculopapular 2 0 0 0
Metabolism and Nutrition
 Dehydration 0 1 0 0